Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2022

View Archived Issues

CD22 aberrant splicing confers resistance to therapy in B-ALL

Dysregulation of the tRNA synthetase modulator NOTCH1 behind T-ALL pathogenesis

Discovery of novel hybrid compounds as antitubercular agents

TuA-derived hPep elicits long-term anticancer immunity in mice

Leo Pharma discloses IL-17 modulators

Amgen and Arrakis collaborate to discover and develop targeted RNA degrader therapeutics

Anaxis Pharma patents MLKL inhibitors

Abbisko Therapeutics identifies new PD-1/PD-L1 interaction inhibitors

Betta Pharmaceuticals synthesizes new HIF-2alpha inhibitors

Wigen Biomedicine Technology presents new CDK inhibitors

CD6-ALCAM pathway is a therapeutic target in SLE

Methamphetamine harnessed for good in BBB transport

REVTx-99 demonstrates in vitro antiviral activity against SARS-CoV-2

PostEra and Pfizer expand strategic collaboration

VCAM-1-targeting polyelectrolyte complex enhances therapeutic efficacy of miR-92a inhibitors in vivo

Dren Bio and Pfizer collaborate to discover and develop bispecific antibodies for cancer

ABL and Sanofi enter collaboration and license agreement for ABL-301

G3PP is a therapeutic target for age-related metabolic diseases

Neogene licenses portfolio of TCRs targeting KRAS and TP53 mutations from NCI

A simple method for the synthesis of isoxazole derivatives with in vitro antitumor activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...